|
|
|
||
Intellectual Property
|
|
PCT applications which claim use of Small Molecules, Mabs, Fragments and antagonists in cardiovascular disorders related to HMGB1 over-expression:
MI 2001A000562 Granted in Italy
WO02074337 Granted in Australia
WO2005074984
PCT application for HMGB1 inhibitors and antagonists which inhibit the Atherosclerotic pathogenesis and progression:
WO2006077614
PCT application for HMGB1 and its fragments use as therapeutic preparations in damaged connective tissue:
WO02074337 Granted in Australia
PCT application for CT301/R use in cardiovascular disorders:
WO2006010628
PCT application for BIOCYSAN (Cysteine/Cystine) use in End Stage Renal Disease:
WO2005058305 Granted in Europe and Mexico
PCT application for BIOCYSAN Plus (Cysteine/Cystina+Glutathione) use in End Stage Renal Disease:
WO2007116428
|
|
|
|
Bio3 News...
|
|
Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the official
opening of a Californian subsidiary, located in Hayward…
more...
You may also notice that we have a new website. This site was built by a company based in the UK called Sinful Design. They can be found at;
www.sinfuldesign.com
|
|
|
